InnovAge
INNV
#6657
Rank
$0.68 B
Marketcap
$5.03
Share price
-2.33%
Change (1 day)
4.57%
Change (1 year)

P/E ratio for InnovAge (INNV)

P/E ratio as of December 2025 (TTM): -39.1

According to InnovAge's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -39.0769. At the end of 2022 the company had a P/E ratio of -25.6.

P/E ratio history for InnovAge from 2021 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2022-25.6-115.39%
2021167

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
AcelRx Pharmaceuticals
ACRX
-0.2783-99.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Horizon Therapeutics
HZNP
60.6-255.01%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Cocrystal Pharma
COCP
-0.7034-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
13.2-133.67%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.